| Domestic Sales | Pharmaceutical products mainly for mother and child healthcare distributed across India. | Strong institutional relationships, regulatory compliance, niche specialization in mother-child therapeutics. | Includes government institutions, hospitals, clinics, and retail pharmaceutical outlets (B2B and B2C). | Specialty drugs and branded formulations in mother and child care segment. | 54 | 72 | Revenue mainly from direct sales to hospitals, clinics, government institutions and pharmaceutical distributors. | Direct sales with price controls influencing margins in certain drugs. | Demand from government and private healthcare sectors; introduction of new products and formulations. | Teclobet, Tanolite, Levotryl series and others |
| Export Sales | Exports pharmaceutical items specialized in mother and child healthcare to international markets. | WHO GMP certification, established export channels, responsive product development for international standards. | International hospitals, clinics, pharmaceutical distributors (primarily B2B). | Specialty exports with WHO compliant GMP manufacturing facility credentials aid premium pricing. | 21 | 28 | Revenue from export sales to hospitals, distributors, pharmacies abroad. | Contract and direct sales with growth driven by expanding global footprint. | Robust 11.4% growth driven by expanded market access and new product registrations. | Specific brands not disclosed, product range mirrors domestic portfolio |
